Pathalys Pharma Strengthens Leadership Team With Appointment Of Dr. Bastian Dehmel As CMO

Pathalys Pharma, Inc., a private biopharmaceutical company focused on advancing kidney disease treatments, has appointed Dr. Bastian Dehmel as Chief Medical Officer. Dr. Dehmel will oversee clinical operations, clinical affairs, clinical sciences, data management/biometrics, and product drug safety. Reporting directly to CEO Neal Fowler, Dr. Dehmel will also be a key member of the Senior Leadership Team.

Neal Fowler, said in a statement, “We are thrilled to welcome Bastian as Pathalys’ Chief Medical Officer. Throughout his career, Bastian has demonstrated exceptional clinical development leadership, and we are confident that his wealth of experience and deep understanding of calcimimetic clinical research and operations will play a crucial role in advancing our lead asset, upacicalcet, towards a successful clinical and regulatory outcome.”

Dr. Bastian Dehmel brings two decades of extensive experience in the global biotechnology and pharmaceutical sectors to Pathalys Pharma. His expertise covers all stages of drug development, from clinical operations and biostatistics to regulatory affairs across diverse therapeutic areas and international markets. Before joining Pathalys, Dr. Dehmel was the Chief Development Officer at Oculis S.A. and previously held the position of Chief Medical Officer at OxThera AB. Earlier in his career, he advanced through various leadership roles at Amgen, culminating in his position as Global Development Executive Medical Director.

Dr. Bastian Dehmel earned his Doctor of Medicine (M.D.) from the Free University Berlin Medical School. He completed his clinical training in Internal Medicine at Charité University in Berlin, Germany, and also at Tulane Medical School in New Orleans, United States.

Dr. Dehmel expressed his excitement by saying, “I am honored to join the leadership team at Pathalys at a very important time in the company’s history. As demonstrated by the tremendous progress Pathalys has made with the phase 3 program for upacicalcet, this company is driven and focused on their mission of transforming patient lives. I sincerely look forward to being a part of this team and to contributing to bringing upacicalcet to dialysis patients in need.”